### OSIRIS Table of Contents

#### Triage
- **T1.0-2.0** Start Protocol
- **T3.0-5.0** Anticipated Risk to Participants

#### Cover Sheet
- **CS1.0** Reason for Submission
- **CS2.0** Study Title and Abstract
- **CS3.0** PI Information
- **CS4.0** Co-Investigators
- **CS5.0** Research Staff
- **CS7.0** CTRC Review
- **CS8.0** Scientific Review
- **CS9.0** Investigational Drug, IND and IDE
- **CS11.0** Sponsor Protocol & Brochure
- **CS12.0** Radiation Safety, Biosafety and Fiscal Review
- **CS15.0** Study Site Information
- **CS16.0** Special Research Subject Population
- **CS17.0** Human Stem Cell Research

#### Section 1 – Objective, Aims, and Background and Significance
- **1.1-1.4** Objective, Aims, and Background and Significance

#### Section 2 – Research Design and Methods
- **2.1** Evaluation of Drug, Biological or Nutritional Supplement
- **2.2** Evaluation of Device for Safety/Effectiveness
- **2.3** Summarize Classification and Methodological Design
- **2.4** Subjects Withdrawn from Effective Therapy
- **2.5** Screening Procedures
- **2.6** Research Interventions/Interactions
- **2.7** Follow Up Procedures
- **2.8** Questionnaires or Survey Instruments
- **2.9-2.10** Routine Medical Care, Blood Samples
- **2.11** Total Duration of Subject’s Participation
- **2.12** Planned Deception
- **2.13** Honest Broker for De-Identification
- **2.14** HIPAA and Identifiable Record Information
- **2.15** Collection and Banking of Tissue or Biological Specimens
- **2.16** Information on Family or Acquaintances
- **2.17-2.18** Outcome Variables and Statistical Analysis
- **2.19** Foreign Country or Culturally Different Site
- **2.20** Investigators at External Sites Directed by PI
- **2.21** Study Involves PA Nursing Home
OSIRIS Table of Contents

Section 3 – Human Subjects
3.1-3.4 Subject Population Information
3.5 Participation of Children
3.6 Participation of Prisoners
3.7 Participation of Pregnant Women
3.8 Involvement of Neonates
3.9 Involvement of Fetal Tissues or Organs
3.10-3.12 Total Subjects, Study Subgroups, Statistical Justification
3.13-3.15 Inclusion/Exclusion Criteria, HIV Serostatus

Section 4 – Recruitment and Informed Consent Procedures
4.1 Recruitment Methods
4.6 Waiver of Signed Informed Consent
4.7 Waiver of Informed Consent for Minimal Risk
4.8 Exception to Informed Consent for “Emergency” Procedure
4.9 Informed Consent Forms
4.10 Adult Subjects Capable of Providing Consent
4.11 Point When Informed Consent Will Be Obtained
4.12-4.14 Informing Subjects, Exception to Policies for Informed Consent

Section 5 – Potential Risks and Benefits
5.1-5.3 Risks
5.4 Physical/Psychological Risk to Pregnant Women/Fetus
5.5 Risk of Genetic Mutation Leading to Birth Defects
5.6 Alternate Diagnostic/Treatment Approaches
5.7 Endpoints Discontinuing Participation
5.8-5.11 Access to Research Data/Documents
5.12-5.13 Participation Offers Direct Benefit, Monitoring Plan
5.14-5.17 Precautions Concerning Privacy and Confidentiality

Section 6 – Costs and Payments
6.1 Subjects or Insurance Providers Charged for Procedures
6.2 Subject Compensation

Section 7 – Qualifications and Source(s) of Support
7.1 Qualifications and Experience of PI and Listed Co-Is
7.2 All Sources of Support
7.3 Financial or Equity Interests of PI and Study Team

Supporting Documentation

-References and other Attachments